Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 2014

View Archived Issues

Novel method described for real-time analysis of single-molecule biological processes over time

Investigators identify novel exon 3 mutation in Shwachman-Bodian-Diamond Syndrome gene

BioMarin Pharmaceuticals presents new information on BMN-701 for Pompe's disease

Preliminary results reported from phase Ib study of rhASM

GL-ONC1 found safe and feasible in phase I trial in head and neck cancer

Argenta achieves milestone in antibacterial drug discovery collaboration with Antabio

Zocere licenses neuroprotectant technology for stroke and other brain trauma

Betagenon begins phase I studies of O-304

TXNIP as a novel therapeutic target for stroke-induced oxidative injury

Alcon initiates first-in-human study of LHA-510 for AMD

Foundation Fighting Blindness provides further support for ReNeuron's ReN-003

UCB and Sanofi collaborate in immune-mediated diseases

Caisson expands HEPtune partnership with Novo Nordisk

NeuroDerm begins enrollment in second phase II study of ND-0612

U.S. researchers report development of compositions for rare genetic disease

Roche prepares new cathepsin S and/or L inhibitors

Rexahn Pharmaceuticals reports data from phase I trial of Supinoxin in solid tumors

Roche researchers present novel SYK inhibitors

Sunshine Lake Pharma discloses new compounds for HBV infection

Aeras begins phase II trial of AERAS-404 vaccine for tuberculosis

USAN Council selects vepoloxamer as unique non-proprietary name for API in MST-188

FDA grants orphan drug status to Rebiotix's C. difficile infection treatment

Innate Pharma continues phase II trial of lirilumab in AML based on DSMB recommendation

Celsus Therapeutics outlines timeline for MRX-6 atopic dermatitis program

Chimerix's brincidofovir pilot trial to begin immediately

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...